The role of palbociclib in thyroid carcinoma with BRAF mutation

Affiliations

¹ Department of Oncology, Veterans Hospital (NIMTS), Athens, Greece.
² Department of Oncology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.
³ Endocrine Unit, 1st Department of Propaedeutic Medicine, Laiko University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

Editorial

Nikolaos Tsoukalas et al. Gland Surg. 2018 Aug.

. 2018 Aug;7(Suppl 1):S82-S85.

doi: 10.21037/gs.2018.03.07.

¹ Department of Oncology, Veterans Hospital (NIMTS), Athens, Greece.
² Department of Oncology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.
³ Endocrine Unit, 1st Department of Propaedeutic Medicine, Laiko University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAF^V600E.
Antonello ZA, Hsu N, Bhasin M, Roti G, Joshi M, Van Hummelen P, Ye E, Lo AS, Karumanchi SA, Bryke CR, Nucera C. Antonello ZA, et al. Oncotarget. 2017 Sep 24;8(49):84743-84760. doi: 10.18632/oncotarget.21262. eCollection 2017 Oct 17. Oncotarget. 2017. PMID: 29156680 Free PMC article.

1. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016;26:1-133. 10.1089/thy.2015.0020 - DOI - PMC - PubMed
1. Ito Y, Suzuki S, Ito K, et al. Tyrosine-kinase inhibitors to treat radioiodine-refracted, metastatic, or recurred and progressive differentiated thyroid carcinoma [Review]. Endocr J 2016;63:597-602. 10.1507/endocrj.EJ16-0064 - DOI - PubMed
1. NCCN clinical practice guidelines in oncology, thyroid carcinoma 2017 Version 2.
1. Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014;384:319-28. 10.1016/S0140-6736(14)60421-9 - DOI - PMC - PubMed
1. Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015;372:621-30. 10.1056/NEJMoa1406470 - DOI - PubMed